Mauna Kea (MKEAF) 5.9000 $MKEAF
Mauna Kea Technologies Announces Positive Results from FOCUS Pivotal Clinical Trial on Use of Confocal Laser Endomicroscopy in Biliary Cancer Detection
PR Newswire - Tue Jan 27, 10:45AM CST
Results published in peer-reviewed journal Gastrointestinal Endoscopy accompanied by editorial noting that the study "pushes the boundaries of diagnosis in indeterminate biliary strictures"
Mauna Kea Technologies Announces Publication of Consensus Report Based on Clinical Evidence on Use of Confocal Laser Endomicroscopy in Gastroenterology
PR Newswire - Tue Jan 20, 10:45AM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced publication of the first consensus recommendations on the clinical use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications, by the peer-reviewed journal United European Gastroenterology. The recommendations were presented in an article entitled: "Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications: a consensus report based on clinical evidence", authored by 26 international experts in gastroenterology and confocal laser endomicroscopy.
Mauna Kea Technologies: Editorial Highlighting Advantages of Needle-based Endomicroscopy for Characterization of Pancreatic Cysts Published in Endoscopy
PR Newswire - Wed Jan 14, 11:30AM CST
-- Editorial accompanies publication of CONTACT 1 Study results showing that needle-based confocal laser endomicroscopy with Cellvizio able to confirm benign serous cystadenomas with 100% specificity.
Mauna Kea Technologies Announces 2014 Sales Growth of +10% to EUR 11.0m
PR Newswire - Wed Jan 07, 11:00AM CST
-- Strong growth in Asia-Pacific region: +52%
Mauna Kea Technologies and Siemens Announce Joint Effort to Evaluate the Use of Cellvizio in Interventional Radiology
PR Newswire - Mon Nov 03, 12:27PM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the unique trans-disciplinary optical biopsy platform, today announced a new collaboration with Siemens Healthcare to evaluate the clinical benefits of Cellvizio® in interventional radiology procedures. Cellvizio's needle-based optical biopsy technology will be used in combination with Siemens Angiography & Interventional X-ray (AX) and Computed Tomography (CT) imaging systems in two clinical studies taking place at the Hôpital Européen Georges Pompidou (HEGP) in Paris and the University Hospital in Strasbourg, France.
Surgeons at Coliseum Northside Hospital Among First in Nation to use Endomicroscopic Imaging With Cellvizio to Identify Esophageal Disease Prior to Anti-Reflux Surgery
PR Newswire - Tue Oct 28, 11:45AM CDT
Mauna Kea Technologies (Euronext : MKEA FR0010609263) and Coliseum Northside Hospital, an HCA hospital, today announced that surgeons at Coliseum Northside Hospital are among the first in the U.S. to use an advanced endomicroscopy technology called Cellvizio to identify pre-cancerous and cancerous cells in patients gastroesophageal reflux disease (GERD). According to guidelines established by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), it is important to take steps to identify and treat pre-cancerous or cancerous cells prior to anti-reflux surgery.
Mauna Kea Technologies: Physicians Using Optical Biopsy with Cellvizio Discover a New Diagnostic Criterion Specific for Benign Pancreatic Cysts and Invisible with Other Imaging Technologies
Business Wire - Tue Oct 21, 11:51AM CDT
--Findings from prospective multicenter CONTACT 1 study published in peer-reviewed journal Endoscopy.
Mauna Kea Technologies : Success and Strong Attendance for Cellvizio at the Annual Chinese Conference of Digestive Endoscopy, Ccdd 2014
Business Wire - Mon Oct 13, 11:07AM CDT
--Several speakers presented the clinical benefits of Cellvizio then demonstrated it in a live procedure performed in front of an audience of over 2,500 Chinese physicians
Mauna Kea Technologies Announces That the French High Authority for Health Has Given a Favorable Opinion for the Inscription of Optical Endomicroscopy for Barrett's Esophagus on the List of Reimbursable Procedures
Business Wire - Mon Oct 13, 10:59AM CDT
Regulatory News:
Mauna Kea Technologies: Major Success for Cellvizio at the EUS 2014 Conference
Business Wire - Tue Sep 23, 11:26AM CDT
--Cellvizio's clinical value for the management of pancreatic cysts was presented by several speakers and then demonstrated during two live medical procedures to the audience of 650 physicians
Mauna Kea Technologies Receives 510(K) Regulatory Clearance from U.S. FDA for New Cellvizio System Functioning in a near-Infrared Wavelength
Business Wire - Tue Jul 29, 10:45AM CDT
--New clearance is an important step on the company's product roadmap
Mauna Kea Technologies Announces Positive Results from FOCUS Pivotal Clinical Trial on Use of Confocal Laser Endomicroscopy in Biliary Cancer Detection
PR Newswire - Tue Jan 27, 10:45AM CST
Results published in peer-reviewed journal Gastrointestinal Endoscopy accompanied by editorial noting that the study "pushes the boundaries of diagnosis in indeterminate biliary strictures"
Mauna Kea Technologies Announces Publication of Consensus Report Based on Clinical Evidence on Use of Confocal Laser Endomicroscopy in Gastroenterology
PR Newswire - Tue Jan 20, 10:45AM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced publication of the first consensus recommendations on the clinical use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications, by the peer-reviewed journal United European Gastroenterology. The recommendations were presented in an article entitled: "Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications: a consensus report based on clinical evidence", authored by 26 international experts in gastroenterology and confocal laser endomicroscopy.
Mauna Kea Technologies: Editorial Highlighting Advantages of Needle-based Endomicroscopy for Characterization of Pancreatic Cysts Published in Endoscopy
PR Newswire - Wed Jan 14, 11:30AM CST
-- Editorial accompanies publication of CONTACT 1 Study results showing that needle-based confocal laser endomicroscopy with Cellvizio able to confirm benign serous cystadenomas with 100% specificity.
Mauna Kea Technologies Announces 2014 Sales Growth of +10% to EUR 11.0m
PR Newswire - Wed Jan 07, 11:00AM CST
-- Strong growth in Asia-Pacific region: +52%
Mauna Kea Technologies and Siemens Announce Joint Effort to Evaluate the Use of Cellvizio in Interventional Radiology
PR Newswire - Mon Nov 03, 12:27PM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the unique trans-disciplinary optical biopsy platform, today announced a new collaboration with Siemens Healthcare to evaluate the clinical benefits of Cellvizio® in interventional radiology procedures. Cellvizio's needle-based optical biopsy technology will be used in combination with Siemens Angiography & Interventional X-ray (AX) and Computed Tomography (CT) imaging systems in two clinical studies taking place at the Hôpital Européen Georges Pompidou (HEGP) in Paris and the University Hospital in Strasbourg, France.
Surgeons at Coliseum Northside Hospital Among First in Nation to use Endomicroscopic Imaging With Cellvizio to Identify Esophageal Disease Prior to Anti-Reflux Surgery
PR Newswire - Tue Oct 28, 11:45AM CDT
Mauna Kea Technologies (Euronext : MKEA FR0010609263) and Coliseum Northside Hospital, an HCA hospital, today announced that surgeons at Coliseum Northside Hospital are among the first in the U.S. to use an advanced endomicroscopy technology called Cellvizio to identify pre-cancerous and cancerous cells in patients gastroesophageal reflux disease (GERD). According to guidelines established by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), it is important to take steps to identify and treat pre-cancerous or cancerous cells prior to anti-reflux surgery.
Mauna Kea Technologies: Physicians Using Optical Biopsy with Cellvizio Discover a New Diagnostic Criterion Specific for Benign Pancreatic Cysts and Invisible with Other Imaging Technologies
Business Wire - Tue Oct 21, 11:51AM CDT
--Findings from prospective multicenter CONTACT 1 study published in peer-reviewed journal Endoscopy.
Mauna Kea Technologies : Success and Strong Attendance for Cellvizio at the Annual Chinese Conference of Digestive Endoscopy, Ccdd 2014
Business Wire - Mon Oct 13, 11:07AM CDT
--Several speakers presented the clinical benefits of Cellvizio then demonstrated it in a live procedure performed in front of an audience of over 2,500 Chinese physicians
Mauna Kea Technologies Announces That the French High Authority for Health Has Given a Favorable Opinion for the Inscription of Optical Endomicroscopy for Barrett's Esophagus on the List of Reimbursable Procedures
Business Wire - Mon Oct 13, 10:59AM CDT
Regulatory News:
Mauna Kea Technologies: Major Success for Cellvizio at the EUS 2014 Conference
Business Wire - Tue Sep 23, 11:26AM CDT
--Cellvizio's clinical value for the management of pancreatic cysts was presented by several speakers and then demonstrated during two live medical procedures to the audience of 650 physicians
Mauna Kea Technologies Receives 510(K) Regulatory Clearance from U.S. FDA for New Cellvizio System Functioning in a near-Infrared Wavelength
Business Wire - Tue Jul 29, 10:45AM CDT
--New clearance is an important step on the company's product roadmap
